169939-94-0

Usage

InChI:InChI=1/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1

Upstream product

• 124-40-3 dimethyl amine 
• 169940-46-9 (9S)-6,7,10,11-tetrahydro-9-{[(methylsulfonyl)oxy]methyl}-9H,18H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]-oxadiazacyclohexadecine-18,20(19H)-dione 
• 68-12-2 N,N-dimethyl-formamide 
• 169940-44-7 (S)-4-(tert-Butyl-diphenyl-silanyloxy)-3-(2-hydroxy-ethoxy)-butan-1-ol 
• 169940-42-5 tert-Butyl-[(S)-4-iodo-2-(2-iodo-ethoxy)-butoxy]-diphenyl-silane 
• 169940-43-6 (S)-3-Allyloxy-4-(tert-butyl-diphenyl-silanyloxy)-butan-1-ol 
• 169940-41-4 (S)-3-Allyloxy-4-(tert-butyl-diphenyl-silanyloxy)-butyric acid methyl ester 
• 169940-55-0 (9S)-6,7,10,11-tetrahydro-9-(hydroxymethyl)-9H,18H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13 ]-oxadiazacyclohexadecine-18,20(19H)-dione 
• 1224599-85-2 (R)-6,7,10,11-tetrahydro-9-[(dimethylamino)methyl]-5,21:12,17-dimetheno-9H-dibenzo[e,k]furo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20-dione 
• 183198-55-2 Methanesulfonic acid (S)-4-(tert-butyl-diphenyl-silanyloxy)-3-(2-methanesulfonyloxy-ethoxy)-butyl ester 

Relevant academic research and scientific papers

Method of manufacturing ruboxistarin

Method of manufacturing ruboxistaurin, comprising the steps of preparation of L-2-deoxyribose 1-cyano-3,4-dibenzoate, followed by deprotection to 1-cyano L-2-deoxyribose, oxidative cleaving to (S)-4-hydroxy-2-(2-hydroxy-ethoxy)-butyronitrile and transform

Macrocyclic bisindolylmaleimides: Synthesis by inter- and intramolecular alkylation

Macrocyclic bisindolylmaleimides 1-4 have been identified as competitive reversible inhibitors of PKC β1 and β2 and are being advanced to the clinic for evaluation as a treatment of retinopathy associated with diabetic complications. Highly convergent and stereoselective syntheses of 1-4 have been developed. The key synthetic step involves intermolecular alkylation of symmetrical bisindolylmaleimide 9 with chiral bisalkylating agent 8c and is amenable to the preparation of multikilogram quantities of these compounds. The synthetic sequence to 1, the most active the compound, proceeds in 11 steps and 26% overall yield (> 98% ee) from (R)-1-chloro-2,3-propanediol. No chromatographic purifications are required throughout the process and the final product is isolated in >97% purity after crystallization from DMF/MeOH. Synthesis of 1-4 by intramolecular alkylation proved less efficient, requiring 17 steps and affording 1-4 in lower overall yields of 6.0-8.5%.

(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21- dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene- 1,3(2H)-dione (LY333531) and related analogues: Isozyme selective inhibitors of protein kinase Cβ

Protein kinase C (PKC) is a family of closely related serine and threonine kinases. Overactivation of some PKC isozymes has been postulated to occur in several disease states, including diabetic complications. Selective inhibition of overactivated PKC iso